Histopathological and immunohistochemical detection of protective effects of University of Wisconsin solution supplemented with iloprost on donor lung damage

Basit Öğe Kaydı
dc.authorid0000-0002-8259-7896
dc.authorid0000-0002-4672-3509
dc.authorid0000-0002-7832-0499
dc.authorid0000-0001-7648-6324
dc.contributor.authorÜstündağ, Nil
dc.contributor.authorBozkurt, A. Kürşat
dc.contributor.authorDemirkaya, Ahmet
dc.contributor.authorKöksal, Cengiz
dc.contributor.authorMayda, Atilla Senih
dc.date.accessioned2021-06-23T19:17:58Z
dc.date.available2021-06-23T19:17:58Z
dc.date.issued2004
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractObjective. Histopathological evaluation and immunohistochemical markers of surfactant B and CD34 were used to detect alveolar type II cell and pulmonary endothelial cell damage in order to assess the efficacy on donor lung protection of University of Wisconsin (UW) solution supplementation with iloprost. Methods. Twelve rats were divided into two groups: UW solution was used alone in group I, and UW iloprost solution in group II. Lung samples were taken at regular intervals for pathological examination to evaluate alveolar cell integrity with hematoxylin and eosin staining. Preservation, of alveolar type II cell and pulmonary endothelial cells was aesessed using surfactant B and CD34 immunomarkers, respectively. Results. In both groups, alveolar integrity, surfactant, and CD34 revealed time-dependent, progressive damage, although this deterioration was less apparent among the iloprost-supplemented group. Alveolar integrity was better preserved at 4, 6, 8, 12, and 48 hours among group II rate. Surfactant staining showed significantly more deterioration at 12 and 24 hours in group I. Similarly, CD34 demonstrated significantly more injury at 6, 12, 24, and 48 hours in group I. Conclusion. Although progressive lung tissue damage assessed by histopathological and immunohistochemical methods was observed in both groups, our findings suggest less deterioration in the iloprost-supplemented group.en_US
dc.identifier.doi10.1016/j.transproceed.2004.05.054
dc.identifier.endpage1274en_US
dc.identifier.issn0041-1345
dc.identifier.issn1873-2623
dc.identifier.issue5en_US
dc.identifier.pmid15251310en_US
dc.identifier.scopus2-s2.0-3142610901en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1271en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2004.05.054
dc.identifier.urihttps://hdl.handle.net/20.500.12491/5600
dc.identifier.volume36en_US
dc.identifier.wosWOS:000222713000014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÜstündağ, Nil
dc.institutionauthorMayda, Atilla Senih
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHistopathologicalen_US
dc.subjectImmunohistochemical
dc.subjectLung
dc.subjectIloprost Solution
dc.subjectSupplemented
dc.titleHistopathological and immunohistochemical detection of protective effects of University of Wisconsin solution supplemented with iloprost on donor lung damageen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
nil-ustundag.pdf
Boyut:
177.52 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/ Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu